{"DataElement":{"publicId":"2841225","version":"1","preferredName":"Malignant Neoplasm Neoplasm Nucleus Percentage Cell Value","preferredDefinition":"Numeric value to represent the percentage of tumor nuclei in a malignant neoplasm sample or specimen.","longName":"NEOPL_NUC_PERC_VAL","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2841223","version":"1","preferredName":"Malignant Neoplasm Neoplasm Nucleus Percentage","preferredDefinition":"A primary or metastatic malignant tumor involving the ovary.  Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors.  Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas. -- 2004:A flat rectangular piece of glass on which specimens can be mounted for microscopic study._An abnormal tissue growth resulted from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant ones exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias. -- 2004:A body within the cell, surrounded by a membrane, within which lie the chromosomes, one or more nucleoli, combined with proteins, and exhibits mitosis.:A fraction or ratio with 100 understood as the denominator._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"NEOPL_MALIG_NUC_PERC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2186369","version":"1","preferredName":"Malignant Neoplasm","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0647F5B-A888-4B87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-03","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2673298","version":"1","preferredName":"Neoplasm Nucleus Percentage","preferredDefinition":"An abnormal tissue growth resulted from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant ones exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias. -- 2004:A body within the cell, surrounded by a membrane, within which lie the chromosomes, one or more nucleoli, combined with proteins, and exhibits mitosis.:A fraction or ratio with 100 understood as the denominator.","longName":"C3262:C13197:C25613","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nucleus","conceptCode":"C13197","definition":"A body within the cell, surrounded by a membrane, within which lie the chromosomes, one or more nucleoli, combined with proteins, and exhibits mitosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3820CB26-9678-3529-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"ONEDATA","dateModified":"2007-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C037D2-382B-5156-E040-BB89AD434881","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181247","version":"1","preferredName":"Cell Percentage Value","preferredDefinition":"information related to the percentage value for a cell count.","longName":"CELL_PTG_VAL","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","format":"%","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208119","version":"1","preferredName":"Percentage Value","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3E46-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B7ECCE-4611-6532-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-19","modifiedBy":"KNABLEJ","dateModified":"2022-03-15","changeDescription":"3/15/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787505","version":"1","longName":"HNSC","context":"NCIP"},{"publicId":"3787508","version":"1","longName":"KIRP","context":"NCIP"},{"publicId":"3787513","version":"1","longName":"LUSC","context":"NCIP"},{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"},{"publicId":"3787502","version":"1","longName":"CESC","context":"NCIP"},{"publicId":"3787503","version":"1","longName":"COAD","context":"NCIP"},{"publicId":"3787506","version":"1","longName":"KICH","context":"NCIP"},{"publicId":"3787507","version":"1","longName":"KIRC","context":"NCIP"},{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"},{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"},{"publicId":"3787510","version":"1","longName":"LGG","context":"NCIP"},{"publicId":"3787509","version":"1","longName":"LAML","context":"NCIP"},{"publicId":"3787511","version":"1","longName":"LIHC","context":"NCIP"},{"publicId":"3787519","version":"1","longName":"SKCM","context":"NCIP"},{"publicId":"3787512","version":"1","longName":"LUAD","context":"NCIP"},{"publicId":"3787517","version":"1","longName":"READ","context":"NCIP"},{"publicId":"3787518","version":"1","longName":"SARC","context":"NCIP"},{"publicId":"3787520","version":"1","longName":"STAD","context":"NCIP"},{"publicId":"3787522","version":"1","longName":"UCEC","context":"NCIP"},{"publicId":"3787521","version":"1","longName":"THCA","context":"NCIP"},{"publicId":"3787515","version":"1","longName":"PAAD","context":"NCIP"}]},{"publicId":"4631580","version":"1","longName":"Exceptional Responder CDEs","context":"CTEP","ClassificationSchemeItems":[{"publicId":"4631582","version":"1","longName":"Exceptional Responder CDEs","context":"CTEP"}]}],"AlternateNames":[{"name":"Percent Tumor Nuclei","type":"TCGA_Name","context":"NCIP"},{"name":"tumor_nuclei_percent","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"% Tumor Nuclei","type":"Preferred Question Text","description":"% Tumor Nuclei","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C037D2-383C-5156-E040-BB89AD434881","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-25","modifiedBy":"TSESU","dateModified":"2018-07-10","changeDescription":"12/11/14 jc added Exceptional Responder CSI.  Curated to support The Cancer Genome Atlas (TCGA) 2009","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}